STOCK TITAN

Harrow (HROW) Stock Price, News & Analysis

HROW NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
29 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
-28% close of March 3, 2026
1-year change
-20.5% closing prices, November 13, 2025 to November 13, 2026
1-month change
+6.7% closing prices, October 13, 2026 to November 13, 2026

Company Description

Harrow, Inc. (Nasdaq: HROW) is an eyecare-focused pharmaceutical company that describes itself as a leading provider of ophthalmic disease management solutions in North America. According to the company, it offers a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, including dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, a range of ocular surface conditions, and retina diseases. Harrow states that it was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes.

Harrow operates in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector. The company’s business is centered on the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. In earlier disclosures, Harrow has described two operating segments: a Branded segment, which includes activities related to FDA-approved ophthalmology pharmaceutical products and the out-licensing of rights to certain branded products, and the ImprimisRx segment, which represents activities in its ophthalmology-focused pharmaceutical compounding business.

Harrow emphasizes that its portfolio spans prescription and non-prescription ophthalmic medications, intended to make eyecare therapies accessible and affordable to millions of Americans. Through its ImprimisRx subsidiary, the company has highlighted its role in ophthalmic compounding and its history of providing compounded medicines used by eyecare professionals across the United States. Harrow characterizes ImprimisRx as a trusted national leader in ophthalmic compounding and notes that it has supplied critical, affordable medicines to many patients over a period of years.

In addition to its established ophthalmic portfolio, Harrow has taken steps to expand into related therapeutic areas. The company has announced the acquisition of Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on non-opioid, non-intravenous (non-IV) therapies for sedation for medical procedures in hospital, outpatient, and in-office settings. Melt’s product candidates, including MELT-210, MELT-300, and MELT-400, are based on the Zydis oral dissolving tablet (ODT) drug delivery platform. Harrow has stated that MELT-300 is a patented, sublingually delivered formulation of a fixed dose of midazolam and ketamine designed to provide rapid, predictable sedation without the need for IV administration, with potential applications in ophthalmology and other medical specialties.

Harrow links this acquisition to its existing perioperative and surgical offerings. The company has previously marketed MKO Melt, a compounded sublingual sedation product sold by ImprimisRx and used by U.S. ophthalmic institutions, primarily for cataract surgery. Harrow has indicated that MELT-300 builds on real-world experience with MKO Melt and has been studied in Phase 2 and Phase 3 clinical programs. The company has described MELT-300 as having demonstrated statistical superiority to midazolam alone in completed clinical trials, and it has outlined plans to pursue a New Drug Application (NDA) and potential commercialization in the United States.

Beyond product development, Harrow has also described initiatives focused on patient access and affordability. The company has launched the VEVYE Access for All (VAFA) program to improve access and affordability for VEVYE (cyclosporine ophthalmic solution) 0.1%, a prescription medication indicated for the treatment of the signs and symptoms of dry eye disease. Building on VAFA, Harrow announced Harrow Access for All (HAFA), which it characterizes as an expansion of its patient access model across its broader ophthalmic portfolio of branded, authorized generics (AGx), and compounded medications. According to Harrow, HAFA is intended to provide a single, unified access point for prescribers and patients, with features such as predictable pricing, streamlined prescribing, and integration with electronic medical record systems.

Harrow has also discussed a digital access platform, referred to as the HarrowAccess.com portal, which it describes as a centralized portal for its specialty, generic, and compounded ophthalmic medications and partner products. The company states that this platform is designed to simplify prior authorizations, reduce administrative burden for prescribers, and provide a more predictable path from prescription to treatment for patients.

From a capital structure and financing perspective, Harrow has reported activities related to debt offerings and credit facilities. The company has announced the pricing of senior unsecured notes due 2030 and the establishment of a senior secured revolving credit facility with a commercial bank. According to Harrow’s disclosures, the proceeds from these notes are expected to be used to repay existing debt, redeem previously issued senior notes, and support general corporate purposes, which may include strategic business development opportunities and related investments. Separate Form 25 filings indicate the removal from listing of certain Harrow senior notes (with specific coupon and maturity profiles) from the Nasdaq Stock Market, following redemption.

Harrow is headquartered in Nashville, Tennessee, and its common stock trades on the Nasdaq Stock Market under the symbol HROW. The company regularly communicates with investors through press releases, investor conferences, and an Investor & Analyst Day, where it provides overviews of its commercial portfolio, development pipeline, and long-term vision. Harrow’s public communications frequently reiterate its focus on ophthalmic disease management, patient access, and the development and commercialization of ophthalmic and related pharmaceutical products.

Business segments and focus areas

According to prior descriptions, Harrow’s operations include:

  • Branded ophthalmic products – FDA-approved ophthalmology pharmaceutical products and related out-licensing activities.
  • ImprimisRx ophthalmic compounding – an ophthalmology-focused pharmaceutical compounding business that supplies compounded medications to U.S. eyecare professionals.
  • Perioperative and procedural sedation candidates – through the acquisition of Melt Pharmaceuticals, focusing on non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210, with potential use in ophthalmic and other outpatient procedures.
  • Access and affordability programs – initiatives such as VAFA and HAFA, which are designed to improve patient access to Harrow’s branded, generic, and compounded ophthalmic medications.

Position within ophthalmic care

Across its disclosures, Harrow consistently frames its role as supporting U.S. eyecare professionals in preserving sight by making ophthalmic medications accessible and affordable. The company highlights its focus on both anterior segment conditions (such as dry eye disease, cataracts, refractive errors, and ocular surface disease) and posterior segment or retina conditions (including wet age-related macular degeneration and other retina diseases). Harrow’s communications also emphasize its interest in addressing unmet needs in ophthalmology and related procedural settings, particularly where non-opioid, needle-free sedation and streamlined access to medications may benefit patients and providers.

Stock Performance

$30.13
+0.03%
+0.01
After hoursChange vs the $30.12 closeLast updated: November 13, 2026 at 16:20
-20.5%
Performance 1 year

Harrow (HROW) closed at $30.12 on November 13, 2026. Over the past 12 months, the price has lost 20.5%.

See what a $1,000 investment in HROW would be worth today

Average down calculator for HROW

HROW Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Harrow has 10 recent news articles, with the latest published 3 days ago. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, partnership, earnings date, acquisition. View all HROW news →

Financial Highlights

Harrow generated $272.3M in revenue in FY2025, retaining a 75.0% gross margin, operating income reached $30.5M (11.2% operating margin), and net income was -$5.1M, reflecting a -1.9% net profit margin. Diluted earnings per share stood at -$0.14. The company generated $43.9M in operating cash flow. The current ratio was 2.20, measuring current assets divided by current liabilities.

$272.3M
Revenue (FY2025)
-$5.1M
Net Income (FY2025)
$43.9M
Operating Cash Flow

Upcoming Events

NOV
17
November 17, 2026 Marketing

Craig-Hallum meetings

Harrow management holding one-on-one investor meetings at the Craig-Hallum Alpha Select Conference in New York on Nov 17, 2026.
NOV
18
November 18, 2026 Marketing

Jefferies presentation

Harrow presentation and investor meetings at Jefferies Global Healthcare Conference on Nov 18, 2026 at 08:00 GMT; live webcast and 90-day replay.
YEAR
2027
2027 Regulatory

NDA submission for MELT-300

Planned NDA submission for MELT-300 in 2027
H1
2027
H1 2027 Regulatory

File NDAs for MELT-300/210

Company on track to file NDAs for MELT-300 and MELT-210 during H1 2027
YEAR
2027
YEAR
2028
2028 Product

MELT-300 commercial launch

Targeted commercial launch of MELT-300 in U.S. sedation market
SEP
15
September 15, 2030 Financial

Notes maturity

Maturity date for the 8.625% senior unsecured notes due Sept 15, 2030.

Harrow has 7 upcoming scheduled events. The next event, "Craig-Hallum meetings", is scheduled for November 17, 2026 (in 2 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the HROW stock price.

Short Interest History

Last 12 Months

Short interest in Harrow (HROW) currently stands at 7.1 million shares, down 5.1% from the previous reporting period, representing 22.4% of the float. Since November 2025, short interest has increased by 17.3%.

Days to Cover History

Last 12 Months

Days to cover for Harrow (HROW) currently stands at 14.1 days, up 25.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 3.9 to 16.6 days.

HROW Company Profile & Sector Positioning

Harrow (HROW) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing HROW often look at related companies in the same sector, including Amphastar Pharmaceuticals, Inc. (AMPH), Pacira BioSciences, Inc. (PCRX), Cronos Group Inc. (CRON), Alvotech (ALVO), and ANI Pharmaceuticals, Inc. (ANIP). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate HROW's relative position within its industry.

Frequently Asked Questions

The current stock price of Harrow (HROW) is $30.13 in after-hours trading as of November 13, 2026.

The market cap of Harrow (HROW) is approximately $1.1B. Learn more about what market capitalization means .

The FY2025 revenue of Harrow (HROW) is $272.3M, from its most recent completed fiscal year.

The FY2025 net income of Harrow (HROW) is -$5.1M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Harrow (HROW) is -$0.14 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Harrow (HROW) is $43.9M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Harrow (HROW) is -1.9% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Harrow (HROW) is 11.2% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Harrow (HROW) is 75.0% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Harrow (HROW), current assets divided by current liabilities, was 2.20 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Harrow (HROW) is $204.4M for FY2025, its most recent completed fiscal year.

The operating income of Harrow (HROW) is $30.5M for FY2025, its most recent completed fiscal year. Learn about operating income.

Harrow, Inc. focuses on ophthalmic disease management solutions in North America. The company describes a comprehensive portfolio of prescription and non-prescription pharmaceutical products that address conditions affecting the front and back of the eye, including dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions, and retina diseases.

Harrow operates in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector. Its activities center on the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market.

In prior descriptions, Harrow has outlined two primary segments: a Branded segment, which includes FDA-approved ophthalmology pharmaceutical products and the out-licensing of rights to certain branded products, and the ImprimisRx segment, which represents its ophthalmology-focused pharmaceutical compounding business.

According to company disclosures, Harrow’s portfolio addresses conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, various ocular surface conditions, and retina diseases.

ImprimisRx is a wholly owned subsidiary of Harrow that operates an ophthalmology-focused pharmaceutical compounding business. Harrow has described ImprimisRx as a trusted national leader in ophthalmic compounding that has provided critical, affordable medicines to U.S. patients through eyecare professionals over many years.

Harrow completed the acquisition of Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV therapies for sedation for medical procedures in hospital, outpatient, and in-office settings. This acquisition adds product candidates such as MELT-300 and MELT-210, which are based on the Zydis oral dissolving tablet platform and are intended to provide sublingual, needle-free sedation, with potential applications in ophthalmology and other medical specialties.

VEVYE Access for All (VAFA) is a program designed to improve access and affordability for VEVYE (cyclosporine ophthalmic solution) 0.1%, indicated for the treatment of the signs and symptoms of dry eye disease. Harrow Access for All (HAFA) expands this model to the company’s broader ophthalmic portfolio of branded, authorized generics, and compounded medications, with the goal of offering a unified access point, predictable pricing, and streamlined prescribing for patients and prescribers.

Harrow is headquartered in Nashville, Tennessee. Its common stock is listed on the Nasdaq Stock Market under the ticker symbol HROW.

Harrow states that it was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. Across its public communications, the company emphasizes supporting U.S. eyecare professionals in preserving sight and addressing significant patient needs in ophthalmology and related procedural care.